EGFR and non-small cell lung carcinoma: Only since 2019 have large-scale nationwide or health care system–wide studies reported real-world outcomes from routine treatment with erlotinib and gefitinib in patients with advanced EGFR-mutant NSCLC from Canada [23], the United States [24], Taiwan [25, 26], Poland [27], Finland [28], and the Netherlands [29, 30].